RECHERCHE :   Cancers ORL
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
INCA 33890-101: A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Part 1a: Histologically or cytologically confirmed advanced or metastatic solid tumors as follows: BC (pure small-cell carcinoma, pure adenocarcinoma, and pure squamous cell carcinoma are exlucded) - CESC - ESCA - GC - GEJ - Mel - MPM - NSCLC (mixed small-cell and non-small cell lung cancer histology is exlcluded - tumors should not exhibit mutations in EFGR, ALK, ROS1, BRAF) - OC (Sertoli-Leydic or germ cell cancers are excluded) - RCC - SCCHN (Carcinoma of the nasopharynx, salivary gland, or nonsquamous histologies are excluded) - TNBC - PAAD - CRC. Part1b: same as part 1a, plus dMMR/MSI-H CRC and MSS-CRC
I
CHUV
NIVO POST-OP: A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN)
cancer épidermoïde de la tête et du cou localement avancé opéré à risque élevé de récidive
III
CHUV
EORTC 1420 (SAKK 10/16): Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0 oropharyngeal carcinoma
Carcinome épidermoïde oropharyngien (OPSCC)
III
CHUV
SGNB6A-001: A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
NSCLC, HNSCC, ESCC, HGSOC, cSCC, cancer du sein HER2 négative avancé, Adénocarcinome oesophagien/adénocarci-nome gastro-oesophagien, cancer de la vessie, cancer degestif, cancer du col de l'utérus
I
CHUV
TAK-676-1002: An open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-676 as single agent and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors
Part 2: Histologically confirmed metastatic or unresectable recurrent SCCHN considered incurable by local therapies (oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, paranasal sinues) - Part 3: Histologically confirmed recurrent locally advanced or metastatic MSI-H/dMMR or MSS/pMMR CRC
I
CHUV, HUG